{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:48:19Z","timestamp":1791276499781,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30973673"],"award-info":[{"award-number":["30973673"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201490"],"award-info":[{"award-number":["81201490"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ijantimicag.2014.07.013","type":"journal-article","created":{"date-parts":[[2014,8,30]],"date-time":"2014-08-30T16:35:57Z","timestamp":1409416557000},"page":"436-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections"],"prefix":"10.1016","volume":"44","author":[{"given":"Taotao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1086\/653683","article-title":"Use of intralesional voriconazole for the treatment of cutaneous Scedosporium apiospermum infection","volume":"51","author":"Azofra","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/17425250903463878","article-title":"Pharmacology and clinical use of voriconazole","volume":"6","author":"Thompson","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2009.01.008","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0035","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/0091270010395510","article-title":"Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers","volume":"52","author":"Lee","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0045","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1439-0507.2012.02186.x","article-title":"Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience","volume":"55","author":"Racil","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0050","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/pgs.11.18","article-title":"Pharmacogenomics of the triazole antifungal agent voriconazole","volume":"12","author":"Mikus","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-010-0914-2","article-title":"Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients","volume":"67","author":"Berge","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0065","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0070","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0075","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0085","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2014.07.013_bib0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2014.07.013_bib0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","article-title":"The pharmacokinetics and safety of intravenous voriconazole \u2013 a novel wide-spectrum antifungal agent","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0100","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.7314\/APJCP.2012.13.5.2415","article-title":"Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis","volume":"13","author":"Zhang","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders","volume":"89","author":"Ueda","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0110","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","article-title":"Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients","volume":"15","author":"Kim","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijantimicag.2004.11.010","article-title":"In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study","volume":"25","author":"Mallie","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0120","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0125","first-page":"255","article-title":"Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene","volume":"63","author":"Kimura","year":"2010","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/00498254.2010.503814","article-title":"Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring","volume":"40","author":"Eiden","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0135","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkm330","article-title":"Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms","volume":"60","author":"Levin","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/gtmb.2011.0084","article-title":"Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations","volume":"16","author":"Zuo","year":"2012","journal-title":"Genet Test Mol Biomark"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0145","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00228-010-0869-3","article-title":"Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism","volume":"66","author":"Shi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2014.07.013_bib0150","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2710.2010.01215.x","article-title":"Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy","volume":"36","author":"Bondareva","year":"2011","journal-title":"J Clin Pharm Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914002489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914002489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T01:23:38Z","timestamp":1538270618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0924857914002489"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.07.013","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}